Clinical role of brexpiprazole in depression and schizophrenia

Therapeutics and Clinical Risk Management

Volumn 13, Issue , 2017, Pages 299-306

  Parikh, Nishant B ^a   Robinson, Diana M ^a   Clayton, Anita H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antipsychotic; Partial agonist; Psychopharmacology; Serotonin dopamine activity modulator

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BREXPIPRAZOLE; CARIPRAZINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

ADJUVANT THERAPY; AKATHISIA; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE;

EID: 85015309830     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S94060     Document Type: Review

References (31)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-285.
2. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-2143.
3. Reddy MS. Depression: the disorder and the burden. Indian J Psychol Med. 2010;32(1):1-2.
4. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.
5. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015;10(2):e0116820.
6. Maeda K, Lerdrup L, Suqino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;351(3):686-687.
7. Rexulti® (brexpiprazole) [full prescribing information]. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf. Accessed January 18, 2016.
8. Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1-6.
9. Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015;25(4):505-511.
10. Yoshimi N, Fujita Y, Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014;124:245-249.
11. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3):356-364.
12. Howland RH. Brexpiprazole: another multipurpose antipsychotic drug? J Psychosoc Nurs Ment Health Serv. 2015;53(4):23-25.
13. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870-880.
14. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1-3):127-135.
15. Correll CU, Skuban A, Ouyang J, Weiss C, Weiller E, Kane JM. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies. Eur Neuropsychopharmacol. 2015;25(suppl 2):S522-S523.
16. Correll CU, Skuban A, Hobart M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;176(1-3):82-92.
17. Lundbeck H. Brexpiprazole in Patients with Acute Schizophrenia. Bethesda, MD: National Library of Medicine (US); 2015.
18. Marder SR, Hakala MJ, Gislum M, et al. An interventional, multicenter, randomized, double-blind, placebo-controlled, active reference, flexible dose study of brexpiprazole in adults with acute schizophrenia. In: 24th European Congress of Psychiatry; Madrid, Spain; 2016.
19. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol. 2016;31(4):192-201.
20. Hobart M, Ouyang J, Forbes A, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study; Miami, FL: United States: American Society of Clinical Psychopharmacology 2015 Annual Meeting; 2015.
21. Fleischhacker WW, Hobart M, Ouyang J, et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: randomised, double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2015;25(suppl 2):S527.
22. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69(9):978-997.
23. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232-1240.
24. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224-1231.
25. McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomized controlled trials. J Affect Disord. 2016;201:116-123.
26. Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker R. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study. Biol Psychiatry. 2015;77(9 suppl 1):S66.
27. Citrome L. The ABCs of dopamine receptor partial agonists-aripiprazole, brexpiprazole, and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211-1220.
28. Menard F, Fava M, Davidsen CK, Baker RA. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study. Biol Psychiatry. 2015;77(9 suppl 1):S65.
29. Krystal A, Mittoux A, Meisels P, Baker R. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study. Biol Psychiatry. 2015;77(9 suppl 1):S64-S65.
30. Skuban A. A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Delphinus Trial. Bethesda, MD: National Library of Medicine (US); 2015.
31. Nelson JC, Skuban A, Zhang P, Weiller E, Weiss C. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies. Poster presentation, 168th Annual Meeting of the American Psychiatric Association Annual Meeting; May 16-20, 2015; Toronto, ON, Canada.